US Patent

US9387191 — Ferric citrate dosage forms

Formulation · Assigned to Keryx Biopharmaceuticals Inc · Expires 2030-07-21 · 4y remaining

Vulnerability score 48/100 Strong — defensible against typical IPR challenges

What this patent protects

This patent protects ferric citrate-containing tablets that meet certain dissolution, tableting, and disintegration standards.

USPTO Abstract

Disclosed herein are ferric citrate-containing tablets. In various embodiments, the tablets include ferric citrate formulations that meet certain dissolution, tableting and disintegration standards. In various aspects, the tablet formulations can include ferric citrate as the active ingredient and a binder. The formulations also can include a lubricant and/or a disintegrant (which, in some embodiments, can be the same as the binder).

Drugs covered by this patent

Patent Metadata

Patent number
US9387191
Jurisdiction
US
Classification
Formulation
Expires
2030-07-21
Drug substance claim
No
Drug product claim
Yes
Assignee
Keryx Biopharmaceuticals Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.